A Clinical Study to Evaluate the Efficacy and Safety of LIV-GAMMA SN Inj. in Primary Immune Thrombocytopenia (ITP)

Last updated: March 29, 2021
Sponsor: SK Plasma Co., Ltd.
Overall Status: Completed

Phase

3

Condition

Immune (Idiopathic) Thrombocytopenic Purpura (Itp)

Thrombocytopenia And Thrombocytopenia Prevention

Thrombosis

Treatment

N/A

Clinical Study ID

NCT03164915
IVIg_ITP_III_2016
  • Ages > 19
  • All Genders

Study Summary

The main purpose of this study is to assess the efficacy and safety of LIV-GAMMA SN Inj. in adult subjects with ITP. The primary objective of this study is to determine the responder rate. A response is defined as a platelet count of ≥30×10^9/L and at least a 2 fold increase of the baseline, confirmed on at least 2 separate occasions at least 7 days apart without bleeding. The secondary objectives are to evaluate the further efficacy assessments including duration of response, and the safety of LIV-GAMMA SN Inj.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Diagnosis of ITP
  • Mean screening platelet count of <30×10^9/L from 3 qualifying platelet countsperformed within 14 days before the start of treatment, with no individual plateletcount above 35×10^9/L.
  • No other factors inducing ITP
  • Stable doses of ITP active treatment must not have modified the dose in the preceding 1 month and must maintain their prestudy dose during the study.

Exclusion

Exclusion Criteria:

  • Known for hypersensitivity reactions to blood products, intravenous immunoglobulin (IVIg) or immunoglobulin G
  • Immunoglobulin A (IgA) deficiency
  • Therapy with live attenuated virus vaccines 3 months before the first administrationof LIV-GAMMA SN Inj.
  • Administration of other investigational product 1 month before the firstadministration of LIV-GAMMA SN Inj.
  • Administration of Rituximab 3 months before the first administration of LIV-GAMMA SNInj.
  • Treatment with anti-coagulants, which may affect the function of platelet
  • Positive HIV, HBV, HCV
  • 3-fold increase of ALT or AST compared to normal upper limit
  • eCFR < 30mL/min/1.73m^2
  • History of deep vein thrombosis (DVT) or IVIg-induced thrombotic compliances
  • Hemoglobin > 10g/dL

Study Design

Total Participants: 37
Study Start date:
October 24, 2016
Estimated Completion Date:
September 28, 2018

Connect with a study center

  • Busan National University Hospital

    Busan,
    Korea, Republic of

    Site Not Available

  • Bundang Seoul National University Hospital

    Seongnam,
    Korea, Republic of

    Site Not Available

  • Samsung Medical Center

    Seoul,
    Korea, Republic of

    Site Not Available

  • Severance Hospital

    Seoul,
    Korea, Republic of

    Site Not Available

  • The Catholic University of Korea, Seoul ST. Mary's Hospital

    Seoul,
    Korea, Republic of

    Site Not Available

  • Yangsan Busan National University Hospital

    Yangsan,
    Korea, Republic of

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.